The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also declined amid slipping oil prices, while Shell edged up after selling its UK and EU renewables portfolio to TotalEnergies. Housebuilders surged as falling gilt yields improved borrowing outlook, supporting mortgage affordability. Meanwhile, global markets saw mixed moves with Wall Street rallying on tech gains and the yen strengthening after coordinated intervention by Japan and the US. Investors remain cautious amid geopolitical tensions and economic data releases ahead.
AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will st...
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
The FTSE 100 rose slightly to 10,888 points despite AstraZeneca shares dropping 7% due to merger talks with Bristol Myers Squibb, which face regulatory scrutiny. Shell agreed to sell its European onshore renewables business to TotalEnergies, reflecti...
AstraZeneca's shares fell 6% following reports of talks to acquire Bristol Myers Squibb, leaving analysts puzzled. Despite AstraZeneca's strong growth and innovation, brokers like Jefferies and UBS question the strategic timing and benefits of the de...
Compugen Ltd. reported progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, expecting median progression-free survival data by Q1 2027, a potential milestone for its COM701 antibody. The company also highlighted advancements in p...
